MADRIGAL PHARMACEUTICALS, INC. (MDGL) Free cash flow
- Free cash flow · 12 months (USD): Value $-206.28M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value -16.07%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-206.28M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-197.72M − $8.57M ≈ $-206.28M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | -16.07% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $-206.28M ÷ $1.28B × 100 ≈ -16.07% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-197.72M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.61× | Operating cash flow / net income. Period ending 2026-06-30. $-197.72M ÷ $-325.10M ≈ 0.61× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -197.72M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations |
| Capital spending | 8.57M USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -206.28M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 1.28B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -325.10M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-206.28M | (m) | $-197.72M | $8.57M | (m) | $1.28B | (m) | $-325.10M | (m) | (m) | -16.07% | 0.61× |
| 2026-03-31 | $-272.41M | (m) | $-268.10M | $4.32M | (m) | $1.13B | (m) | $-309.44M | (m) | (m) | -24.05% | 0.87× |
| 2025-12-31 | $-190.02M | (m) | $-189.55M | $467.00K | (m) | $958.40M | (m) | $-288.28M | (m) | (m) | -19.83% | 0.66× |
| 2025-09-30 | $-161.63M | (m) | $-160.58M | $1.05M | (m) | $740.64M | (m) | $-289.13M | (m) | (m) | -21.82% | 0.56× |
| 2025-06-30 | $-308.39M | (m) | $-307.41M | $974.00K | (m) | $515.55M | (m) | $-281.90M | (m) | (m) | -59.82% | 1.09× |
| 2025-03-31 | $-396.41M | (m) | $-395.31M | $1.10M | (m) | $317.38M | (m) | $-391.59M | (m) | (m) | -124.90% | 1.01× |
| 2024-12-31 | $-457.03M | (m) | $-455.57M | $1.46M | (m) | $180.13M | (m) | $-465.89M | (m) | (m) | -253.72% | 0.98× |
| 2024-09-30 | $-433.32M | (m) | $-431.02M | $2.30M | (m) | $76.81M | (m) | $-518.67M | (m) | (m) | -564.13% | 0.83× |
| 2024-06-30 | $-450.82M | (m) | $-448.95M | $1.86M | (m) | $14.64M | (m) | $-510.45M | (m) | (m) | -3079.78% | 0.88× |
| 2024-03-31 | $-391.12M | (m) | $-389.32M | $1.80M | (m) | $0.00 | (m) | $-444.27M | (m) | (m) | (m) | 0.88× |
| 2023-12-31 | $-325.71M | (m) | $-324.23M | $1.48M | (m) | $0.00 | (m) | $-373.63M | (m) | (m) | (m) | 0.87× |
| 2023-09-30 | $-303.28M | (m) | $-302.81M | $472.00K | (m) | (m) | (m) | $-347.34M | (m) | (m) | (m) | 0.87× |
| 2023-06-30 | $-277.13M | (m) | $-276.96M | $166.00K | (m) | (m) | (m) | $-329.80M | (m) | (m) | (m) | 0.84× |
| 2023-03-31 | $-259.21M | (m) | $-259.01M | $200.00K | (m) | (m) | (m) | $-314.73M | (m) | (m) | (m) | 0.82× |
| 2022-12-31 | $-225.07M | (m) | $-224.86M | $217.00K | (m) | (m) | (m) | $-295.35M | (m) | (m) | (m) | 0.76× |
| 2022-09-30 | $-214.69M | (m) | $-214.39M | $301.00K | (m) | (m) | (m) | $-273.99M | (m) | (m) | (m) | 0.78× |
| 2022-06-30 | $-201.20M | (m) | $-200.88M | $318.00K | (m) | (m) | (m) | $-255.90M | (m) | (m) | (m) | 0.79× |
| 2022-03-31 | $-190.62M | (m) | $-190.40M | $217.00K | (m) | (m) | (m) | $-246.82M | (m) | (m) | (m) | 0.77× |
| 2021-12-31 | $-184.13M | (m) | $-183.92M | $209.00K | (m) | $0.00 | (m) | $-241.85M | (m) | (m) | (m) | 0.76× |
| 2021-09-30 | $-190.92M | (m) | $-190.81M | $106.00K | (m) | $0.00 | (m) | $-236.42M | (m) | (m) | (m) | 0.81× |
| 2021-06-30 | $-193.17M | (m) | $-193.11M | $59.00K | (m) | $0.00 | (m) | $-231.28M | (m) | (m) | (m) | 0.83× |
| 2021-03-31 | $-170.55M | (m) | $-170.48M | $64.00K | (m) | $0.00 | (m) | $-218.66M | (m) | (m) | (m) | 0.78× |
| 2020-12-31 | $-157.90M | (m) | $-157.56M | $334.00K | (m) | $0.00 | (m) | $-202.24M | (m) | (m) | (m) | 0.78× |
| 2020-09-30 | $-115.35M | (m) | $-114.90M | $458.00K | (m) | (m) | (m) | $-170.86M | (m) | (m) | (m) | 0.67× |
| 2020-06-30 | $-78.82M | (m) | $-78.37M | $453.00K | (m) | (m) | (m) | $-134.33M | (m) | (m) | (m) | 0.58× |
| 2020-03-31 | $-66.10M | (m) | $-65.65M | $445.00K | (m) | (m) | (m) | $-105.00M | (m) | (m) | (m) | 0.63× |
| 2019-12-31 | $-41.80M | (m) | $-41.62M | $172.00K | (m) | (m) | (m) | $-83.95M | (m) | (m) | (m) | 0.50× |
| 2019-09-30 | $-35.65M | (m) | $-35.61M | $46.00K | (m) | (m) | (m) | $-67.68M | (m) | (m) | (m) | 0.53× |
| 2019-06-30 | $-29.58M | (m) | $-29.52M | $61.00K | (m) | (m) | (m) | $-54.77M | (m) | (m) | (m) | 0.54× |
| 2019-03-31 | $-23.40M | (m) | $-23.34M | $62.00K | (m) | (m) | (m) | $-41.53M | (m) | (m) | (m) | 0.56× |
| 2018-12-31 | $-25.53M | (m) | $-25.51M | $22.00K | (m) | (m) | (m) | $-32.81M | (m) | (m) | (m) | 0.78× |
| 2018-09-30 | $-25.20M | (m) | $-25.19M | $14.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $-24.90M | (m) | $-24.90M | $1.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $-27.31M | (m) | $-27.19M | $124.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-22.44M | (m) | $-22.32M | $125.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $-21.78M | (m) | $-21.65M | $127.08K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | $-25.94M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | $-20.94M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $-17.61M | (m) | $-17.61M | $3.08K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $-81.75M | (m) | $-81.73M | $19.48K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | $30.28M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $-71.50M | (m) | $-71.44M | $58.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $-71.42M | (m) | $-71.32M | $99.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $-74.41M | (m) | $-74.29M | $123.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $-79.07M | (m) | $-78.92M | $144.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | $-78.57M | (m) | $-78.40M | $167.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | $-76.57M | (m) | $-76.42M | $146.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | $-75.98M | (m) | $-75.47M | $516.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-78.18M | (m) | $-77.41M | $769.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | $-72.02M | (m) | $-71.24M | $771.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | $-68.88M | (m) | $-67.92M | $964.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | $-61.73M | (m) | $-61.09M | $634.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $-54.64M | (m) | $-54.13M | $505.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | $-52.90M | (m) | $-52.10M | $803.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | $-51.51M | (m) | $-50.66M | $857.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | $-50.54M | (m) | $-49.72M | $827.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $-47.99M | (m) | $-47.30M | $690.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-38.34M | (m) | $-38.20M | $136.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-27.26M | (m) | $-26.81M | $454.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |